Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.

Slides:



Advertisements
Similar presentations
Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
Sakthivel Selvaraj, Habib Hasan, Preeti Kumar, Maulik Chokshi Public Health Foundation of India, India 1.
Differences in the availability of medicines used for chronic and acute conditions in developing countries Alexandra Cameron International Conference on.
First Evaluation of Good Governance for Medicines Programme Brief Summary of Findings.
Presented to CSO workshops in Kabwe on 18 July 2014, Livingstone on 28 July 2014 and Lusaka on 27 August 2014.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Medicines Transparency Alliance Presented by Deirdre Dimancesco Department of Essential Medicines and Health Products, WHO at the Technical Briefing Seminar.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Making Services Work: Indicators, Assessments and Benchmarking of Governance in Health and Education Dena Ringold, Senior Economist, The World Bank APPAM.
Access to Medicine Index 3 rd International Conference for Improving the Use of Medicines Poster 599 Tuesday 15 th November 2011.
Identifying, finding and analyzing the component costs of Essential Medicines WHO/HAI Medicine Prices Project.
Analysis of the Pharmaceutical Supply Chain in Jordan Simon Conesa 1, Prashant Yadav 1, Rania Bader 2 (2009) 1 MIT-Zaragoza International Logistics Program,
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan WHO/HAI Project on Medicine Prices & Availability Cost Plus Price Setting.
MULTI-STAKEHOLDER COLLABORATION: CAN IT IMPROVE TRANSPARENCY, DISCLOSURE AND ACCESS TO MEDICINES? EXPERIENCES FROM 7 META PILOT COUNTRIES Wilbert Bannenberg.
Wilbert Bannenberg, Technical Director MeTA International Secretariat IACC 14 Bangkok, 13 November 2010 MeTA multi-stakeholder process – a way to improve.
Wilbert Bannenberg SARPAM
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Data Disclosure: An Ongoing Progress Towards Transparency Abeer Rabayah B.Sc Pharmacy -MBA /Marketing MeTA National Coordinator.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
Contact Monitoring Regional Network (CMKN). Why procurement It is estimated that an effective public procurement system could save as much as 25% of government.
Rasha Hamra, PharmD, MPH Ministry of Health, Lebanon Antalya, November 17, 2011 Transparency Monitoring Study: A Rapid Assessment of Transparency in Key.
Medicines Transparency Alliance14/10/ Medicines promotion: innovative tools to promote rational use Carole Piriou Project officer Rational use of.
1 Towards a Medicines Transparency Alliance (MeTA) Richard Laing and Ali Cameron with slides prepared by Michael Borowitz, DfID WHO Technical Briefing.
4 th - 18 November 2011 ICIUM 2011 Conference Antalya, Turkey 16/10/2015.
Samia Saad 1, Birgit Kerstens 2, Wilbert Bannenberg 1,2 1 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2 Health Research for Action (HERA),
Medicines Transparency Alliance18/10/ Towards Improving Availability of Essential Medicines in Jordan’s Public Health Sector Presenter Name Job Title.
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
ACCESS TO MEDICINES - POLICY AND ISSUES
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
Medicines Transparency Alliance27/10/ MeTA Ghana Augustina Koduah (Mrs) Country Coordinator.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Availability of children’s medicines in Africa, 2007 Jane Robertson, Gilles Forte, Suzanne Hill.
Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Medicines Transparency Alliance15/11/ MEDICINES AVAILABILITY - PHILIPPINES Alexander A. Padilla Undersecretary of Health Vice Chairman, MeTA Philippines.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Medicines Transparency Alliance Presented by Gilles Forte Department of Essential Medicines and Health Products, WHO On behalf of WHO and HAI Technical.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Medicines Transparency Alliance16/12/ MeTA Uganda: Promotion Nazeem Mohamed MeTA Council Co-Chair.
Medicines Transparency Alliance16/12/2015 Pricing: Observations Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
Indicators for monitoring and assessing pharmaceutical situation in countries Dr. Edelisa D. Carandang Drug Action Program (DAP) Essential Drugs and Medicines.
Portfolio Committee for Health Medicines and Related Substances Amendment Bill (06/08/08) IMSA represents Research Based Pharmaceutical Companies.
Centre for Research and Analysis of Public Opinion and Predictions EL- PIKIR Methodology of WHO/HAI (Health Action International)Methodology of WHO/HAI.
Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines.
Wilbert Bannenberg Technical Director, Intl MeTA Secretariat 28 April 2010, IPC meeting, Copenhagen Medicines Transparency Alliance: improving people’s.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team.
Wilbert Bannenberg SARPAM
WHO Medicines Work in Countries: The Kenya Example
Richard Laing EMP/WHO TBS 2012
Dr Samvel Azatyan Technical Officer Regulatory Support
Erica Westenberg September 28, 2017
National Medicines Policies
Richard Laing WHO/PAU TBS 2013
National Medicines Policies
Presentation transcript:

Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom Country comparison of MeTA baseline pharmaceutical sector scan data November 2011MeTA

Objective To provide a cross-country comparative snapshot analysis of the baseline information about the pharmaceutical sector in each of the seven MeTA pilot countries November 2011

Design (1)  The MeTA pilot countries collected and reported pharmaceutical sector data for more than 250 indicators  Criteria for selecting the most "representative" indicators per form were: – which indicator reflects the form topic the best ? – which indicator is the most relevant for transparency purposes? – which indicator is the easiest to collect for comparison purposes? November 2011

Design (2)  Cross-country analysis: 45 core (  ) and secondary indicators relating to  Medicine prices (1 + consumer & procurement prices)  Quality (13)  Availability (8)  Promotion (4)  Transparency and accountability (18) November 2011

Design (3)  A traffic light analysis was added to the multi-country comparative table to show the degree of availability and disclosure of the data:  Available and disclosed  Available but not disclosed  Not available at all November 2011

Cross-country tables (1) November 2011

Cross-country tables (2) November 2011

Key findings on indicators (1) November 2011 QUALITY:  Ind : List of registered products is publicly available, identifying originator brands, branded generics and generics

Key findings on indicators (2) November 2011 AVAILABILITY:  Ind. 23.7: Availability of basket of key medicines in health care facilities:

Key findings on indicators (3) November 2011 PROMOTION:  Ind. 18.3: Pharmaceutical companies are required to report promotion and advertising budget in taxes disclosures:

Key findings on indicators (4) November 2011 TRANSPARENCY AND ACCOUNTABILITY:  Ind. 25.1: Legal provisions exist to govern the licensing and prescribing practice of prescribers and health facilities:

Key findings on indicators (5) November 2011 PRICES:  Ind. 14.4: Regulations exist mandating that retail medicine price information should be publicly accessible:

Key findings on indicators (6) November 2011 CONSUMER PRICESLow price generics Atenolol 50mg Cap/tabGhanaJordanKyrgyzstanPeruPhilippinesUganda Public sector110,2819,5921,300,0020,300,86 Private sector110,28450,5524,9842,2327,884,32 Salbutamol 0.1mg/dose inhalerGhanaJordanKyrgyzstanPeruPhilippinesUganda Public sector328,01103,00239,46113,13-1,26 Private sector445,16221,62241,19935,476,041,51  Ind : Consumer prices:

Key findings on indicators (7) November 2011 PROCUREMENT PRICESPublic sector Atenolol 50mg Cap/tabGhanaJordanKyrgyzstanPeruPhilippinesUganda Low price generics2,320,480,800,002,501,02 Originator medicines 5,30 Salbutamol 0.1mg/dose inhalerGhanaJordanKyrgyzstanPeruPhilippinesUganda Low price generics0,831,511,172,582,801,07 Originator medicines 1,96 3,20  Ind : Procurement prices:

Challenges & recommendations  Information gap: ensure that key pharmaceutical information is widely available and disseminated in the public domain November 2011

Challenges & recommendations  Information gap: ensure that key pharmaceutical information is widely available and disseminated in the public domain  Comparison gap: ensure that data collection is compliant with instructions (e.g. consumer and procurement prices) November 2011

Challenges & recommendations  Information gap: ensure that key pharmaceutical information is widely available and disseminated in the public domain  Comparison gap: ensure that data collection is compliant with instructions (e.g. consumer and procurement prices)  Disclosure gap: ensure that public data, regulations, lists are disclosed in a transparent and accessible way (through websites and other publishing platforms) November 2011

Dissemination Individual country pharmaceutical sector scans and the cross-country analysis have been placed in the public domain: medicinestransparency.org/ ICIUM abstract: 967 November 2011

Samia Saad 1, Birgit Kerstens 2, Wilbert Bannenberg 1,2 1 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2 HERA, Belgium COUNTRY COMPARISON OF META BASELINE DATA DISCLOSURE SURVEYS November 2011MeTA

Objective Provide snapshot and compare status of data disclosure of all seven MeTA pilot countries Highlight common areas of transparency/disclosure and gaps in information. November 2011

Methodology/Design Cross country comparison of available disclosed information in core MeTA areas of quality, availability, price and promotion of medicines List of 37 core indicators developed out of recommended 'key types of data to disclose', listed in instructions and guidance for conducting survey Data extracted from qualitative information supplied within individual country survey reports into cross country table (EXCEL) Traffic light analysis applied to cross-country table using where applicable Green = available and disclosed Orange = available but restricted access Red = not available at all November 2011

Output Cross Country Comparison Table that captures practice on what data is actually disclosed at time surveys were conducted in a ‘Selected Indicators’ table Accompanying ‘Explanatory Notes’ table and a ‘Key Findings’ table November 2011

Cross-country Tables (1) - Sample of Key Indicators November 2011

Cross-country Tables (2) – Sample of Traffic Light Analysis November 2011

Key Findings (1) QUALITY 1.1 Market registration procedures and registration status of all medicines Indicator 1. Process for registering and de-registering medicines – Pilot countries disclose clear guidelines for registering medicines on respective regulatory agency websites, underpinned by legislation disclosed. – Exception: Kyrgyzstan - registration requirements only available to private companies upon request from regulator. 1.4 Quality Assurance data during registration or procurement Indicators 8. & 9. – Quality testing information available in most countries, but access restricted to drug regulators. No disclosure. – Exception: Peru's DIGEMID Health Control and Monitoring Division publishes list of products that failed quality control testing on its website. November 2011

Key Findings (2) November 2011 AVAILABILITY 2.4Volume & value of medicines procured in the public and non- profit sectors Indicator 21. Government budgets for pharmaceuticals for last fiscal year Public sector budget information difficult to access. Exception: Jordan and Kyrgyzstan – budgets published on MoH and Ministry of Finance websites respectively. Budget information from Peru, the Philippines and Zambia available but access restricted. Lack of transparency because no laws mandating disclosure of budgets for health and pharmaceuticals – budgets distributed across different public sector institutions. No data supplied in surveys of Ghana and Uganda.

Key Findings (3) PRICE 3.1 Consumer and ex-manufacture prices of medicines in the public, private, and non-profit sectors Indicator 28. Private sector retail prices for list of key essential medicines Only Jordan sets medicines retail prices and publishes information though searchable database (but not user friendly). No information due to lack of systematic price monitoring in Ghana, Kyrgyzstan, Uganda and Zambia. In Peru and Philippines, partial information available through recently implemented new legislation: Government Maximum Retail Price (Philippines) and recently launched Price Observatory (Peru). All seven countries have median price ratios of a basket of 30 essential medicines through WHO/HAI surveys conducted within last seven years. November 2011

Key Findings (3) PRICE 3.3 Medicines price components in public, non-profit, & private sectors Indicator 34. & 35. Data on price components (duties, taxes, mark-ups and other charges) for key essential medicines (domestically manufactured or imported) Overall data not available. Only Ghana and Philippines data disclosed through WHO/HAI surveys (specifically included price component data). Apart from Jordan, countries don’t regulate mark ups on medicines prices. Jordan publishes its regulations but not absolute value of mark ups for individual medicines. Taxes: Majority of MeTA countries still impose taxes on medicines. Some medicines are tax exempt in Peru; Zambia waives taxes on essential medicines. November 2011

Key Findings (4) PROMOTION 4.1 Medicines promotion regulations, policies, and industry practices Indicator 36. List of manufacturers and distributors that subscribe to internationally or nationally recognized codes of conduct Information not available in any of the seven MeTA countries. Indicator 37. Number and type of violations regarding promotional practices and how complaints were resolved Information not available in any MeTA pilot countries, although all seven countries have guidelines on medicines promotion and regulation criteria for direct to consumer advertising, which is monitored by the regulator. Monitoring and disclosing violations to ethical guidelines for promotion of medicines weak in all MeTA countries. November 2011

Conclusions - Cross country Comparison DISCLOSURE enables comparison of level of transparency of pharmaceutical sectors of seven diverse pilot countries highlights similarities/difference s and assesses where there is room for improvement of data disclosure. GAPS Information not available (deficiency in health information management system) Other key data not included in comparison - not addressed well in individual surveys (Explanatory Notes). November 2011 Non Disclosure

Dissemination All the MeTA Baseline tools are available as part of the ‘Core Tools’ in the MeTA Toolkit at Individual Country Baseline Data Disclosure Survey Reports can be found and downloaded at countries/ countries/ Country Comparison of MeTA Data Disclosure Survey can be found at countries/country-comparison/ November 2011